Celltrion's CT-P51 biosimilar to Keytruda receives FDA nod for phase 3 study
Celltrion said Monday that it has received approval from the U.S. Food and Drug Administration (FDA) for the investigational new drug (IND) application for a phase 3 clinical trial of CT-P51, its biosimilar to Keytruda (pembrolizumab). With this IND …